Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting | November 06, 2017

November 6, 2017 — Elderly patients undergoing...

Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients
News | Antiplatelet and Anticoagulation Therapies | November 03, 2017

November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests...

Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting | November 01, 2017

November 1, 2017 — OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at...

COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies | September 12, 2017

September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with...

EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation | September 01, 2017

September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with...

Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies | August 28, 2017

August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc. announced results from an analysis of real-world data...

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies | August 18, 2017

August 18, 2017 — Medtronic plc announced a global randomized...

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies | August 16, 2017

August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI)...

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies | August 03, 2017

August 3, 2017 — Abbott recently announced the first patient has been enrolled in a...

Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies | July 25, 2017

July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs)...

Alere point of care POC testing for INR
News | Point of Care Testing | July 17, 2017 | Dave Fornell

July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is...

long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies | July 12, 2017

June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet...

FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies | June 29, 2017

June 29, 2017 — Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA)...

radial access, transradial access trial using anticoagulants
News | Radial Access | June 15, 2017

June 15, 2017 — In patients undergoing ...

Cost comparison between NOACs, novel oral anticoagulants
News | Antiplatelet and Anticoagulation Therapies | May 31, 2017

May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare...

Overlay Init